68
Discover us

25 November 2024

Watch the recorded session of our opnMe online seminar from November 14, 2024, to discover how the selective Cathepsin C (CatC) inhibitor, BI-9740, from opnMe has helped elucidate new roles of CatC signaling in immune response and cardiovascular disease.

51
Discover us

5 November 2024

We recently had the chance to speak to Laura-Marie Zimmermann, a former postdoctoral researcher at the University Hospital Cologne, about her experience with opnMe and her interaction with scientists from Boehringer Ingelheim.

46
Discover us

28 October 2024

Christian Wolfrum, VP of Research and Professor at the Department of Health Sciences and Technology at ETH Zurich, shared his collaboration experience with Boehringer Ingelheim, enabled through an opn2EXPERTS question on opnMe.

66
Collaborate with us

09 September 2024

The Fms-like tyrosine kinase 3 (FLT3) receptor is expressed by bone marrow progenitors at different stages of lymphoid and myeloid development. When the natural ligand binds to the FLT3 receptor, it triggers receptor dimerization...

23
Collaborate with us

01 July 2024

Technical advances in genome sequencing, including long read sequencing, became very popular in recent years allowing us to overcome technical challenges in linking disease phenotypes to nucleotide polymorphisms. For the first time, we are...

Discover us

Hear from our collaborators

slide 1 to 2 of 13